JankovicV1, PascalFrancis, Checkpoint, bibRecord, 000153

Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl- phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice

Identifieur interne : 000153 ( PascalFrancis/Checkpoint ); précédent : 000152; suivant : 000154

Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl- phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice

Auteurs : L Zou [États-Unis] ; JING XU [États-Unis] ; J Jankovic [États-Unis] ; YI HE [États-Unis] ; S Appel [États-Unis] ; W Le [États-Unis]

Source :

Neuroscience letters [ 0304-3940 ] ; 2000.

RBID : Pascal:00-0187522

Descripteurs français

Pascal (Inist)
- Peroxydation, Lipide, Neurotoxine, Dopamine, Locus niger, Pramipexole, Antiparkinsonien, Parkinson maladie, Antioxydant, Neuroprotecteur, Modèle animal, Souris.

English descriptors

KwdEn :
- Animal model, Antioxidant, Antiparkinson agent, Dopamine, Lipids, Locus niger, Mouse, Neuroprotective agent, Neurotoxin, Parkinson disease, Peroxidation, Pramipexole.

Abstract

Pramipexole has been showed to protect cultured dopaminergic (DAergic) cells against free radical-induced cytotoxicity. To test if pramipexole is protective against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated nigral DAergic injury in vivo and if such protection is related to inhibition of lipid peroxidation, DAergic function and lipid peroxidation were determined in MPTP-treated C57BU6 mice. We reported that MPTP administration induced a 38.1% increase of lipid peroxidation product thiobarbituric acid reactive substance (TBARS) in nigra, a 46.7% decrease of tyrosine hydroxylase -positive nigral DAergic neurons and a 59.4% reduction of striatal DA levels. However, pramipexole treatment significantly inhibited the TBARS production by 76%, and attenuated the MPTP-induced decreases in nigral DAergic neurons and striatal DA levels by about 50%. This study suggests that pramipexole can inhibit free radical-mediated lipid peroxidation and protect MPTP-induced nigral injury.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000161
to stream PascalFrancis, to step Curation: 000005

Links to Exploration step

Pascal:00-0187522

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl- phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice</title>
<author><name sortKey="Zou, L L" sort="Zou, L L" uniqKey="Zou L" first="L" last="Zou">L Zou</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jing Xu" sort="Jing Xu" uniqKey="Jing Xu" last="Jing">JING XU</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yi He" sort="Yi He" uniqKey="Yi He" last="Yi">YI HE</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Appel, S H" sort="Appel, S H" uniqKey="Appel S" first="S" last="Appel">S Appel</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Le, W D" sort="Le, W D" uniqKey="Le W" first="W" last="Le">W Le</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0187522</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0187522 INIST</idno>
<idno type="RBID">Pascal:00-0187522</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000161</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000005</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000153</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl- phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice</title>
<author><name sortKey="Zou, L L" sort="Zou, L L" uniqKey="Zou L" first="L" last="Zou">L Zou</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jing Xu" sort="Jing Xu" uniqKey="Jing Xu" last="Jing">JING XU</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yi He" sort="Yi He" uniqKey="Yi He" last="Yi">YI HE</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Appel, S H" sort="Appel, S H" uniqKey="Appel S" first="S" last="Appel">S Appel</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Le, W D" sort="Le, W D" uniqKey="Le W" first="W" last="Le">W Le</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuroscience letters</title>
<title level="j" type="abbreviated">Neurosci. lett.</title>
<idno type="ISSN">0304-3940</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuroscience letters</title>
<title level="j" type="abbreviated">Neurosci. lett.</title>
<idno type="ISSN">0304-3940</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal model</term>
<term>Antioxidant</term>
<term>Antiparkinson agent</term>
<term>Dopamine</term>
<term>Lipids</term>
<term>Locus niger</term>
<term>Mouse</term>
<term>Neuroprotective agent</term>
<term>Neurotoxin</term>
<term>Parkinson disease</term>
<term>Peroxidation</term>
<term>Pramipexole</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Peroxydation</term>
<term>Lipide</term>
<term>Neurotoxine</term>
<term>Dopamine</term>
<term>Locus niger</term>
<term>Pramipexole</term>
<term>Antiparkinsonien</term>
<term>Parkinson maladie</term>
<term>Antioxydant</term>
<term>Neuroprotecteur</term>
<term>Modèle animal</term>
<term>Souris</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Pramipexole has been showed to protect cultured dopaminergic (DAergic) cells against free radical-induced cytotoxicity. To test if pramipexole is protective against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated nigral DAergic injury in vivo and if such protection is related to inhibition of lipid peroxidation, DAergic function and lipid peroxidation were determined in MPTP-treated C57BU6 mice. We reported that MPTP administration induced a 38.1% increase of lipid peroxidation product thiobarbituric acid reactive substance (TBARS) in nigra, a 46.7% decrease of tyrosine hydroxylase -positive nigral DAergic neurons and a 59.4% reduction of striatal DA levels. However, pramipexole treatment significantly inhibited the TBARS production by 76%, and attenuated the MPTP-induced decreases in nigral DAergic neurons and striatal DA levels by about 50%. This study suggests that pramipexole can inhibit free radical-mediated lipid peroxidation and protect MPTP-induced nigral injury.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0304-3940</s0>
</fA01>
<fA02 i1="01"><s0>NELED5</s0>
</fA02>
<fA03 i2="1"><s0>Neurosci. lett.</s0>
</fA03>
<fA05><s2>281</s2>
</fA05>
<fA06><s2>2-3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl- phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ZOU (L.-L.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JING XU</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>JANKOVIC (J.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>YI HE</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>APPEL (S. H.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LE (W.-D.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, One Baylor Plaza</s1>
<s2>Houston, TX 77030</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>167-170</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17240</s2>
<s5>354000086896150240</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>20 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0187522</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neuroscience letters</s0>
</fA64>
<fA66 i1="01"><s0>IRL</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Pramipexole has been showed to protect cultured dopaminergic (DAergic) cells against free radical-induced cytotoxicity. To test if pramipexole is protective against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated nigral DAergic injury in vivo and if such protection is related to inhibition of lipid peroxidation, DAergic function and lipid peroxidation were determined in MPTP-treated C57BU6 mice. We reported that MPTP administration induced a 38.1% increase of lipid peroxidation product thiobarbituric acid reactive substance (TBARS) in nigra, a 46.7% decrease of tyrosine hydroxylase -positive nigral DAergic neurons and a 59.4% reduction of striatal DA levels. However, pramipexole treatment significantly inhibited the TBARS production by 76%, and attenuated the MPTP-induced decreases in nigral DAergic neurons and striatal DA levels by about 50%. This study suggests that pramipexole can inhibit free radical-mediated lipid peroxidation and protect MPTP-induced nigral injury.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Peroxydation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Peroxidation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Peroxidación</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lipide</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Lipids</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Lípido</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Neurotoxine</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Neurotoxin</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Neurotoxina</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Locus niger</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Locus niger</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Locus níger</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Pramipexole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Pramipexole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Pramipexol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Antioxydant</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Antioxidant</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Antioxidante</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Neuroprotecteur</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Neuroprotective agent</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Neuroprotector</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Modèle animal</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Animal model</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Modelo animal</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Souris</s0>
<s5>54</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Mouse</s0>
<s5>54</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Ratón</s0>
<s5>54</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>29</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>29</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>29</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>30</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>30</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>30</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>32</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>32</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>32</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>33</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>33</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>33</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>136</s1>
</fN21>
</pA>
</standard>
</inist>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Zou, L L" sort="Zou, L L" uniqKey="Zou L" first="L" last="Zou">L Zou</name>
</region>
<name sortKey="Appel, S H" sort="Appel, S H" uniqKey="Appel S" first="S" last="Appel">S Appel</name>
<name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J Jankovic</name>
<name sortKey="Jing Xu" sort="Jing Xu" uniqKey="Jing Xu" last="Jing">JING XU</name>
<name sortKey="Le, W D" sort="Le, W D" uniqKey="Le W" first="W" last="Le">W Le</name>
<name sortKey="Yi He" sort="Yi He" uniqKey="Yi He" last="Yi">YI HE</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000153 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000153 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    JankovicV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:00-0187522
   |texte=   Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl- phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice
}}

This area was generated with Dilib version V0.6.19.
Data generation: Wed Feb 10 22:03:07 2016. Site generation: Tue Feb 13 16:14:27 2024

	Serveur d'exploration autour de Joseph Jankovic
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration autour de Joseph Jankovic

Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl- phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice

Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl- phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri